Home » Newsletters » BioWorld Science

BioWorld Science

April 26, 2013

View Archived Issues

BMS-986015 shows efficacy in a novel animal model of lymphoma

Recommended phase II dose for Genopep-1 determined

Alchemia signs multitarget drug discovery collaboration with AstraZeneca

Nutrition Science Partners commences first trial in phase III ulcerative colitis program

CCG-203971 inhibits Rho-regulated transcription in metastatic melanoma cell lines

Kyowa Hakko Kirin reviews highlights of first quarter 2013

First clinical results of CNV-2197944 presented

arGEN-X progresses ARGX-113 into preclinical development for autoimmune disorders

Dose-finding phase II study of ARX-04 Sufentanil NanoTab achieves primary endpoint

MBio Diagnostics completes phase I of tuberculosis serology program

New TNF-like ligand 1a-binding antibodies designed at Cephalon

Mochida files for Japanese approval of treprostinil

Summit reports encouraging results from phase I trial of novel antibiotic

Dosing begins in phase I study of antibody for treatment of AL amyloidosis

Lambrolizumab designated as breakthrough therapy by the FDA

Immunomic Therapeutics reports results from study of Japanese red cedar allergy vaccine

XBiotech begins enrollment in phase III trial of True Human anticancer antibody

Achaogen to receive additional funding from BARDA for phase III study of plazomicin

BioMarin files MAA with EMA for enzyme replacement therapy Vimizim

Bronchitol phase III trial does not meet primary endpoint

Aubagio delays onset of clinically definite MS in TOPIC study

Treatment with novel D1 receptor agonist leads to cognitive enhancement in patients with SPD

AZD-8186 described as a potent and selective PI3Kbeta inhibitor

Spanish researchers disclose novel compounds with antileishmanial activity

New start-up company focused on rare diseases is created

Novartis presents new isocitrate dehydrogenase inhibitors

Taiwanese scientists divulge novel cannabinoid CB1 receptor antagonists

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...